Enliven Therapeutics (NASDAQ:ELVN) Insider Sells $535,000.00 in Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) insider Joseph Lyssikatos sold 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $26.75, for a total value of $535,000.00. Following the completion of the sale, the insider owned 745,188 shares in the company, valued at $19,933,779. The trade was a 2.61% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Enliven Therapeutics Stock Performance

Enliven Therapeutics stock opened at $25.78 on Friday. The firm has a market cap of $1.53 billion, a price-to-earnings ratio of -14.01 and a beta of 0.41. Enliven Therapeutics, Inc. has a 52-week low of $13.30 and a 52-week high of $29.98. The firm has a 50 day moving average price of $20.43 and a two-hundred day moving average price of $20.36.

Enliven Therapeutics (NASDAQ:ELVN) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.43) by $0.11. As a group, equities research analysts predict that Enliven Therapeutics, Inc. will post -1.95 EPS for the current fiscal year.

Institutional Trading of Enliven Therapeutics

Large investors have recently made changes to their positions in the company. Vestal Point Capital LP increased its position in Enliven Therapeutics by 364.0% in the 3rd quarter. Vestal Point Capital LP now owns 1,160,000 shares of the company’s stock valued at $23,745,000 after buying an additional 910,000 shares in the last quarter. TCG Crossover Management LLC bought a new stake in shares of Enliven Therapeutics during the second quarter valued at approximately $9,990,000. Duquesne Family Office LLC raised its position in shares of Enliven Therapeutics by 104.6% during the third quarter. Duquesne Family Office LLC now owns 947,405 shares of the company’s stock worth $19,393,000 after purchasing an additional 484,405 shares during the period. Candriam S.C.A. bought a new position in shares of Enliven Therapeutics in the 2nd quarter worth $8,358,000. Finally, Franklin Resources Inc. grew its position in Enliven Therapeutics by 2,029.3% in the 2nd quarter. Franklin Resources Inc. now owns 430,240 shares of the company’s stock valued at $8,631,000 after purchasing an additional 410,034 shares during the period. 95.08% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

ELVN has been the topic of a number of recent analyst reports. Wall Street Zen raised Enliven Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Enliven Therapeutics in a research note on Wednesday. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Enliven Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $41.00.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.